Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models

Marlene C. Artime, Brian B. Haines, James Watters et al.|Cancer Research|2010

Cited by 1